SPRINT.ST
Sprint Bioscience AB (publ) [SPRINT.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SPRINT.ST Stock Summary
In the News
SPRINT.ST Financial details
Company Rating
-
Market Cap
87.97M
Income
-419K
Revenue
50.49M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
28
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-12.74
Forward P/E
-
PEG
1.28
P/S
2.7
P/B
3.26
P/C
-
P/FCF
9.85
Quick Ratio
1.78
Current Ratio
1.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-99.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-66.57%
Revenue last 5Y
8.52%
Revenue Q/Q
-72.51%
EPS Q/Q
-117.61%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-41%
ROC
-0.28%
Gross Margin
78%
Oper. Margin
-23%
Profit Margin
-21%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.451-3.28
52W High
-
52W Low
-
RSI
32
Rel Volume
0.74
Avg Volume
267.35K
Volume
196.98K
Perf Week
-14.93%
Perf Month
-10.6%
Perf Quarter
-67.87%
Perf Half Y
-69.65%
-
-
-
-
Beta
0.611
-
-
Volatility
0.04%, 0.03%
Prev Close
0.33%
Price
0.604
Change
-9.04%
Company Profile
- Volume Average 267.35K
- Market Capitalization 87.97M
- Employee 28
- CEO Johan Emilsson
- Headquarters Huddinge,SE
- IPO Date 2014-11-07
-
Website
https://www.sprintbioscience.com 
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
